Peregrine Provides 3D Monte-Carlo-Based Dose Calculations for Radiation Therapy

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 9 No 11
Volume 9
Issue 11

The image shows the radiation therapy treatment plan for a seven-field conformal boost to the prostate, using Peregrine, a 3D Monte-Carlo-based dose calculation system. Monte Carlo simulates the trillions of radiation particles that enter the body during treatment and develops a detailed computerized map of the radiation dose the patient will receive. The technology, developed at the Lawrence Livermore National Laboratory and licensed to NOMOS Corporation, has received FDA clearance for marketing. Image courtesy of NOMOS and the Lawrence Livermore National Laboratory, Livermore, California.

The image shows the radiation therapy treatment plan for a seven-field conformal boost to the prostate, using Peregrine, a 3D Monte-Carlo-based dose calculation system. Monte Carlo simulates the trillions of radiation particles that enter the body during treatment and develops a detailed computerized map of the radiation dose the patient will receive. The technology, developed at the Lawrence Livermore National Laboratory and licensed to NOMOS Corporation, has received FDA clearance for marketing. Image courtesy of NOMOS and the Lawrence Livermore National Laboratory, Livermore, California.

Recent Videos
5 experts are featured in this series
2 experts are featured in this series.
5 experts are featured in this series
2 experts are featured in this series.
Taletrectinib showed improved efficacy in patients with ROS1-positive non–small cell lung cancer who were treatment-naïve.
“It’s a drug that I’m very comfortable with, and it is a drug I’ll likely use primarily in the first-line setting,” stated Jorge Nieva, MD, on taletrectinib in non–small cell lung cancer.
4 experts in this video
4 experts in this video
Those being treated for peritoneal carcinomatosis may not have to experience the complication rates or prolonged recovery associated with surgical options.
For patients with peritoneal carcinomatosis, integrating PIPAC into a treatment regimen does not interrupt their systemic therapy.
Related Content